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We investigated offspring sex ratio among 6232 offspring born to 3218 survivors of childhood cancer in relation to therapeutic
irradiation, and pooled our data with those from two other large-scale studies giving a total of 9685 offspring. Exposure to high-dose
gonadal irradiation was not associated with a significant alteration in offspring sex ratio compared to low doses (men: P¼0.58,
women: P¼0.66). There was also no evidence that the ratio varied with time since cancer diagnosis when comparing survivors
treated with radiotherapy vs those without (men: P¼0.51; women: P¼0.46). This, the largest study to date, finds no evidence that
exposure to radiation affects the offspring sex ratio among survivors of childhood cancer.
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Several studies (Schull and Neel, 1958; Schull et al, 1966; Hawkins,
1991; Dickinson et al, 1996; Byrne et al, 1998; Maconochie et al,
2001; Green et al, 2003; Winther et al, 2003) have investigated
whether parental preconceptional exposure to radiation alters the
sex ratio (boy/girl ratio) of offspring, but most (Schull et al, 1966;
Hawkins, 1991; Byrne et al, 1998; Maconochie et al, 2001;
Green et al, 2003; Winther et al, 2003) have failed to find
supporting evidence. This may be because offspring sex ratio is
not a sensitive indicator of radiation-induced genetic damage
(Neel et al, 1990). It is also possible, however, that the studies
lacked adequate statistical power. Survivors of childhood cancer
provide a unique opportunity to investigate the effect of radiation
on sex ratio because a large proportion of survivors have been
exposed to high doses of therapeutic radiation (Boice et al, 2003).
We have investigated the subject within a large-scale cohort
study of adult survivors of childhood cancer, providing us with
more offspring born to childhood cancer survivors compared
to the largest of the previous studies, which investigated the
effect of gonadal dose (Byrne et al, 1998), and pooled our data with
those from previous large-scale studies, in order to maximise
statistical power.
MATERIALS AND METHODS
Study design
We used data from the British Childhood Cancer Survivor Study
(BCCSS), which is a population-based cohort study of survivors of
childhood cancer who were 16 years or older, had been diagnosed
with childhood cancer between 1940 and 1991, in Britain, and who
had survived for at least 5 years. As part of the BCCSS, a
questionnaire that included details of adverse health outcomes and
the sex of any offspring was sent to 14540 survivors in the cohort.
In total, 10477 returned the questionnaire, yielding a response rate
of 72%. Twenty-seven per cent reported having produced at least
one child, with a total of 5433 offspring born to 2793 survivors. As
part of an earlier investigation (Hawkins, 1991), General Practi-
tioners of 2286 survivors were sent a questionnaire that also
enquired about the sex of any survivor offspring. Although most
survivors included in this latter study were also included in the
more recent comprehensive investigation, 425 survivors did not
complete the more recent questionnaire, but their GP at the time
had provided us with information on their offspring. This allowed
us to add 799 offspring to the existing 5433 offspring available for
this investigation, giving a total number of 6232 offspring born to
3218 survivors.
Data relating to cancer type and site, radiotherapy treatment
(yes/no), chemotherapy treatment (yes/no), and demographics
were obtained from the National Registry of Childhood Tumours.
The information on tumour site, together with information on
whether the survivor had been treated with radiotherapy, allowed
us to determine whether the gonads of the survivor had been
exposed to relatively high or low doses of radiation. Treatment
with radiotherapy was considered to result in a relatively high
gonadal dose if the site of the irradiated tumour had been between
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treatment was presumed to result in a relatively low gonadal dose
if the tumour had not been irradiated or the irradiation had
occurred below the knee or above the diaphragm (hereafter low
gonadal dose).
Statistical analysis
We expected that radiation induced sex-linked lethal mutations
would manifest as an increase in the offspring sex ratio in male
survivors and as a decrease in female survivors (Schull and Neel,
1958). First, we calculated the offspring sex ratio for all childhood
cancer survivors and compared it with the offspring sex ratio
observed in the general population of England and Wales (Office of
National Statistics, 2002). We then compared the offspring sex
ratio of survivors treated with chemotherapy only, or radiotherapy
only, with that of survivors treated without chemotherapy or
radiotherapy. However, because not all radiotherapy is likely to
have resulted in a high gonadal dose, we calculated the offspring
sex ratio of survivors who had been treated with a high gonadal
dose and the offspring sex ratio of survivors who had been treated
with a low gonadal dose. Subsequently, we estimated the odds ratio
(OR), which expressed the offspring sex ratio (i.e. the odds of
offspring being of male sex) of those treated with a high gonadal
dose relative to that of those treated with a low gonadal dose by
means of unconditional logistic regression, while adjusting for the
potential confounders of treatment with chemotherapy, parental
age (in 5-year groups), and birth order. However, as this
adjustment left the estimates unchanged, we report only crude
ORs.
As radiation-induced germ cell mutations may be repaired or be
followed by cell death, an observed effect may vary with time. We
therefore examined whether the association, if any, between
treatment with radiotherapy and offspring sex ratio varied by the
time interval between diagnosis and birth of offspring. Specifically,
we calculated ORs comparing survivors exposed to radiotherapy
only with survivors not exposed to radiotherapy or chemotherapy
according to different levels of the time interval between diagnosis
and birth of offspring (o10/10–14/15–19/X20 years), and tested
whether these ORs varied significantly from each other. In
addition, we performed a test for trend to examine whether the
log odds of offspring being of male sex increased or decreased
linearly over the different categories of this time interval.
In addition, the findings from this study were pooled with those
from studies by Winther and Byrne (Byrne et al, 1998; Meistrich
and Byrne, 2002; Winther et al, 2003). Byrne et al (1998) defined
potential mutagenic irradiation as treatment with radiotherapy
above the knee and below the diaphragm, and therefore we
considered these survivors as being exposed to high-dose gonadal
irradiation. Survivors treated with alkalyting agents were also
included in this group, because, in their calculation of the sex ratio,
Byrne et al (1998) did not distinguish between those survivors
treated with high gonadal radiation and those treated with
alkalyting agents as both treatments were hypothesised to be
potentially germ-cell mutagenic. Winther et al (2003) used a
classification scheme from low to high to categorise survivors by
the likelihood of the gonads having been exposed to therapeutic
irradiation. To pool our data with this latter study, we regarded the
category defined as high as that in which survivors had been
exposed to high gonadal doses.
RESULTS
The sex ratio for offspring of male and female survivors was 1. 02
(95% CI: 0.94, 1.10) and 1.08 (95% CI: 1.01–1.15), respectively,
which is indistinguishable from the sex ratio of 1.05 observed in
the general population of England and Wales. For male and female
survivors, no significant difference (P¼0.69; P¼0.72, respec-
tively) was found between the sex ratio of those treated with
radiotherapy only vs survivors treated without any radiation
or chemotherapy (Table 1). Neither was treatment with chemo-
therapy only associated with a significant alteration in sex ratio in
males (P¼0.98) or females (P¼0.99). Also no statistically
significant difference in sex ratio between the offspring of
survivors of each sex treated with high-gonadal dose irradiation
vs those treated with low-gonadal dose irradation (males: P¼0.58;
females: P¼0.66). For survivors exposed to high gonadal doses,
the most common diagnosis was Wilms’ tumour (62.7%), followed
by bone tumour (9.7%) and soft-tissue sarcoma (8.3%).
The sex ratio did not vary significantly over time intervals
between diagnosis and birth of offspring when comparing
survivors treated with radiotherapy only with those treated without
(males: pheterogeneity¼0.51, females: pheterogeneity¼0.46). There was
also no significant linear relationship between offspring sex ratio
and time interval between diagnosis and birth of offspring (males:
ptrend¼0.46, females: ptrend¼0.74). For the three studies com-
bined, sex ratios did not differ significantly for survivors treated
with high dose gonadal irradiation vs those treated with low
gonadal doses ((males: P¼0.94), females: P¼0.31) Table 2.
DISCUSSION
This study, which was based upon a greater number of cancer
survivor offspring than available from any previous study, found
no evidence for an altered sex ratio among the offspring of
Table 1 Offspring sex ratio by sex of parent according to different types
of treatment
Male survivors Female survivors
All survivors 1.02 (1221/1198)
a 1.08 (1725/1858)
a
Treated with RT only 0.95 (436/457) 1.09 (485/445)
Treated without RT or CT 1.00 (278/279) 1.13 (496/440)
OR (95% CI)
b 0.96 (0.77, 1.18) 0.97 (0.81, 1.16)
Treated with CT only 1.00 (92/92) 1.13 (152/135)
Treated without CT or RT 1.00 (278/279) 1.13 (496/440)
OR (95% CI)
c 1.00 (0.72, 1.40) 1.00 (0.77, 1.30)
High-dose gonadal RT 0.96 (140/146) 1.03 (187/181)
Low-dose gonadal RT 1.03 (1058/1029) 1.08 (1628/1501)
OR (95% CI)
d 0.93 (0.73, 1.19) 0.95 (0.77, 1.18)
CI¼confidence interval; CT¼chemotherapy; OR¼odds ratio; RT¼radiotherapy.
Number of boys vs girls given in paranthesis.
aTotal number of offspring was 6232, but
for 230 offspring sex was unknown.
bOR expressing the sex ratio for those treated
with RT only vs those treated without RT or CT.
cOR expressing the sex ratio for
those treated with CT only vs those treated without RT or CT.
dOR expressing the
sex ratio for those treated with high-dose gonadal RT vs those with low doses.
Table 2 Sex ratio of survivors treated with potentially high-dose gonadal
irradiation vs those treated with presumed low-dose gonadal irradiation,
based on pooling of data from the current study, that of Winther et al
(2003) and that of Byrne et al (1998)
Boys/girls ratio among
survivors treated with
Sex survivor High gonadal dose Low gonadal dose OR
a (95% CI)
Males 1.01 (272/269)
b 1.02 (1773/1742)
b 0.99 (0.83, 1.19)
Females 0.97 (308/318)
b 1.06 (2570/2433)
b 0.92 (0.78, 1.08)
CI¼confidence interval; OR¼odds ratio.
aORs expressing the sex ratio of those
treated with high-gonadal dose radiation vs those treated with low doses.
bNo. of
boys/girls.
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gonadal irradiation. These findings are consistent with an earlier
report from Denmark by Winther et al (2003). Although non-
significant, Byrne et al (1998) and Meistrich and Byrne (2002)
previously reported a sex ratio of 0.84 among female survivors who
had been treated with potentially mutagenic therapy vs a sex ratio
of 1.03 among those who had been treated with presumed less or
non-mutagenic therapy. However, Byrne et al (1998) also included
survivors who had been treated with potentially mutagenic-
alkylating agents. We were unable to investigate the separate
effects of these agents, which may explain the small difference with
our findings. Consistent with the findings of Winther et al (2003),
we did not find evidence that the offspring sex ratio changes with
time since cancer diagnosis.
A limitation of this study might be that information on the
offspring sex ratio was based on questionnaire data and, inherent
to such an approach, the fact that not all survivors responded.
However, the high proportion of eligible survivors returning a
questionnaire, together with the fact that respondents were similar
to nonrespondents with regard to treatment factors, gives grounds
for regarding response bias as not important.
Another limitation might be related to other known or unknown
factors influencing the offspring sex ratio such as, for example,
time of conception on different days of the menstrual cycle
(Harlap, 1979), though it is unlikely that such factors would
confound the association between exposure to gonadal irradiation
and offspring sex ratio.
Apart from the atomic bomb survivor study (Schull et al, 1966),
most studies conducted to date have either included relatively few
offspring of parents who were exposed to potentially germ-cell
mutagenic irradiation, or the offspring were produced by parents
who were exposed to relatively low gonadal doses of irradiation
compared with childhood cancer survivors. The strength of this
study is the large number of offspring born to survivors
(n¼6232), more than 2.5-fold that included in the largest previous
study (n¼2198) (Byrne et al, 1998; Meistrich and Byrne, 2002)
that investigated the effect of gonadal dose. Even with these
numbers, insufficient statistical power may have led to some small
alterations in the sex ratio going undetected. However, as observed
by Neel et al (1990), it is probable that sex ratio is not a sensitive
indicator of radiation-induced genetic damage in humans. The
discovery of the Lyonisation phenomenon, which established that,
in women, only one X-chromosome in each somatic cell is actually
active, may be relevant. By pooling our data with those from
previous studies, we have maximised the statistical power available
to address the variation in sex ratio, and we have reduced the
plausible size of any hypothesised effect.
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